190 related articles for article (PubMed ID: 34092057)
21. Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.
Hengeveld PJ; van der Klift MY; Kolijn PM; Davi F; Kavelaars FG; de Jonge E; Robrecht S; Assmann JLJC; van der Straten L; Ritgen M; Westerweel PE; Fischer K; Goede V; Hallek M; Levin MD; Langerak AW
Blood; 2023 Feb; 141(5):519-528. PubMed ID: 36084320
[TBL] [Abstract][Full Text] [Related]
22. The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications.
Moia R; Patriarca A; Schipani M; Gaidano G
Cancer J; 2021 Jul-Aug 01; 27(4):266-274. PubMed ID: 34398553
[TBL] [Abstract][Full Text] [Related]
23. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.
Nadeu F; Royo R; Clot G; Duran-Ferrer M; Navarro A; Martín S; Lu J; Zenz T; Baumann T; Jares P; Puente XS; Martín-Subero JI; Delgado J; Campo E
Blood; 2021 May; 137(21):2935-2946. PubMed ID: 33211804
[TBL] [Abstract][Full Text] [Related]
24. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia.
Kanduri M; Cahill N; Göransson H; Enström C; Ryan F; Isaksson A; Rosenquist R
Blood; 2010 Jan; 115(2):296-305. PubMed ID: 19897574
[TBL] [Abstract][Full Text] [Related]
25. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
Rodríguez-Vicente AE; Díaz MG; Hernández-Rivas JM
Cancer Genet; 2013 Mar; 206(3):49-62. PubMed ID: 23531595
[TBL] [Abstract][Full Text] [Related]
26. The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.
Gladstone DE; Blackford A; Cho E; Swinnen L; Kasamon Y; Gocke CD; Griffin CA; Bolaños-Meade J; Jones RJ
Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):132-7. PubMed ID: 22285608
[TBL] [Abstract][Full Text] [Related]
27. Mutation pattern of paired immunoglobulin heavy and light variable domains in chronic lymphocytic leukemia B cells.
Ghiotto F; Marcatili P; Tenca C; Calevo MG; Yan XJ; Albesiano E; Bagnara D; Colombo M; Cutrona G; Chu CC; Morabito F; Bruno S; Ferrarini M; Tramontano A; Fais F; Chiorazzi N
Mol Med; 2011; 17(11-12):1188-95. PubMed ID: 21785810
[TBL] [Abstract][Full Text] [Related]
28. Combined patterns of IGHV repertoire and cytogenetic/molecular alterations in monoclonal B lymphocytosis versus chronic lymphocytic leukemia.
Henriques A; Rodríguez-Caballero A; Nieto WG; Langerak AW; Criado I; Lécrevisse Q; González M; Pais ML; Paiva A; Almeida J; Orfao A
PLoS One; 2013; 8(7):e67751. PubMed ID: 23844084
[TBL] [Abstract][Full Text] [Related]
29. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
30. Chronic lymphocytic leukemia in a young population.
Alshemmari SH; Hamdah A; Pandita R; Kunhikrishnan A
Leuk Res; 2021 Nov; 110():106668. PubMed ID: 34492597
[TBL] [Abstract][Full Text] [Related]
31. Analysis of LPL gene expression in patients with chronic lymphocytic leukemia.
Bilous N; Abramenko I; Chumak A; Dyagil I; Martina Z
Exp Oncol; 2019 Mar; 41(1):39-45. PubMed ID: 30932419
[TBL] [Abstract][Full Text] [Related]
32. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis.
Parikh SA; Strati P; Tsang M; West CP; Shanafelt TD
Blood; 2016 Apr; 127(14):1752-60. PubMed ID: 26841802
[TBL] [Abstract][Full Text] [Related]
33. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
34. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.
Delgado J; Doubek M; Baumann T; Kotaskova J; Molica S; Mozas P; Rivas-Delgado A; Morabito F; Pospisilova S; Montserrat E
Am J Hematol; 2017 Apr; 92(4):375-380. PubMed ID: 28120419
[TBL] [Abstract][Full Text] [Related]
35. Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHV
Burns A; Alsolami R; Becq J; Stamatopoulos B; Timbs A; Bruce D; Robbe P; Vavoulis D; Clifford R; Cabes M; Dreau H; Taylor J; Knight SJL; Mansson R; Bentley D; Beekman R; Martín-Subero JI; Campo E; Houlston RS; Ridout KE; Schuh A
Leukemia; 2018 Feb; 32(2):332-342. PubMed ID: 28584254
[TBL] [Abstract][Full Text] [Related]
36. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.
Bulian P; Rossi D; Forconi F; Del Poeta G; Bertoni F; Zucca E; Montillo M; Pozzato G; D'Arena G; Efremov DG; Marasca R; Lauria F; Gaidano G; Gattei V; Laurenti L
J Transl Med; 2012 Jan; 10():18. PubMed ID: 22289136
[TBL] [Abstract][Full Text] [Related]
37. CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.
Baumann T; Delgado J; Santacruz R; Martínez-Trillos A; Rozman M; Aymerich M; López C; Costa D; Carrió A; Villamor N; Montserrat E
Br J Haematol; 2016 Jan; 172(1):48-55. PubMed ID: 26559905
[TBL] [Abstract][Full Text] [Related]
38. Change in IgHV Mutational Status of CLL Suggests Origin From Multiple Clones.
Osman A; Gocke CD; Gladstone DE
Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):97-99. PubMed ID: 28041846
[TBL] [Abstract][Full Text] [Related]
39. Expression of
Plešingerová H; Janovská P; Mishra A; Smyčková L; Poppová L; Libra A; Plevová K; Ovesná P; Radová L; Doubek M; Pavlová Š; Pospíšilová Š; Bryja V
Haematologica; 2018 Feb; 103(2):313-324. PubMed ID: 29122990
[TBL] [Abstract][Full Text] [Related]
40. The
Perez-Chacon G; Zapata JM
Front Immunol; 2021; 12():627602. PubMed ID: 33912159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
